Compound formula mannitol injection liquid

Abstract

A compound mannitol injection without crystal eduction is prepared from mannitol (5-18 Wt%), sorbitol (2-20), and the water for injection (rest).

Description

technical field [0001] The invention relates to the field of medical drugs, in particular to a formula of compound mannitol injection. This formula contains both Mannitol and Sorbitol. The compound mannitol injection has no crystallization at low room temperature, solves the crystallization problem of the mannitol injection, and is an ideal mannitol preparation with convenient clinical use and few adverse reactions. Background technique [0002] 20% Mannitol Injection is widely used in clinical neurosurgery as an agent to reduce intracranial pressure and free radical scavenger. At present, mannitol is the first choice for the treatment of cerebral edema and lowering intracranial pressure. It has a significant effect in reducing intracranial pressure, and there is no obvious "rebound phenomenon". Since the 20% mannitol solution is a supersaturated solution, during clinical use, the crystallization of mannitol injection has brought great inconvenience to clinical use. In us...

AI Technical Summary

Problems solved by technology

[0004] The invention provides a medical compound mannitol injection, which aims to replace the existing medical mannitol injection, so as to solve the problem that the current mannitol injection is easy to crystallize and precipitate in a low temperature environment (when the room temperature is low), which leads to infusion reactions. and other adverse consequences, providing convenience for clinical use